INTRODUCTION
Multiple myeloma (MM) is a chronic malignant B-cell disorder characterized by plasma cell infiltration in the bone marrow, and a monoclonal immunoglobulin in serum and/or urine. 1 Patients with MM have a variety of clinical signs and symptoms, with approximately 80% experiencing a pathological fracture over the course of their disease and 90% will have bone lesions. 2 Fractures and skeletal pain are thus a very important disease manifestation in this patient population.
According to recent studies, MM is always preceded by the precursor condition monoclonal gammopathy of undetermined significance (MGUS). 3 However, not all MGUS patients develop MM, and the risk for transformation to MM, lymphoma or amyloidosis has been reported to be 1-1.5% per year. 4 While patients with MGUS are asymptomatic, they may have increased morbidity and mortality. [5] [6] [7] Previous smaller studies found that MGUS patients have an increased risk for fractures 2, 5, 8, 9 , and that the prevalence of MGUS is high in patients with osteoporosis [9] [10] [11] ; however it is unclear whether this is associated with MM transformation or related to MGUS per se. Based on small numbers, patterns of fracture risk in relation to MGUS immunoglobulin (Ig) isotype and concentration of the monoclonal-(M)-protein concentration are inconsistent. 2, 8 Furthermore, some, but not all, investigators have found abnormal bone resorption markers in MGUS patients compared to healthy controls. [12] [13] [14] [15] Using high-quality population-based data from Sweden, we assessed the risk of fractures in 5,326 MGUS patients compared to 20,161 population-based matched controls. We further explored risk of fractures in relation to MGUS isotype and Mprotein concentration at diagnosis.
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MATERIALS AND METHODS

Central registries, patients and controls
The details of the study population have been described previously. 16 In Sweden, a clinician who detects a patient with an M-protein, will typically consult with a hematologist at a hospital-based centre, and refer the patient for further work-up, to rule out a lymphoproliferative malignancy.
We established a nationwide MGUS cohort from a national hospital network 
Statistical analysis
Cox proportional hazard models (PROC PHREG, SAS version 9. were estimated overall and separately for men and women. Adjustment variables included in the models were sex, age at diagnosis, and year of diagnosis in quartiles. In 6 addition to gender, models were stratified by MGUS isotype and M-protein concentration at diagnosis. P-values for heterogeneity of effects by MGUS isotype were computed by including appropriate interaction terms in the models. To compute p-values for heterogeneity for risk of axial (skull, vertebral/pelvis, and sternum/costae) versus distal (arm and leg) fractures, we duplicated the cohort and added an indicator variable with value zero for the original cohort and value one for the duplicated cohort. We then counted axial fractures as events in the original and distal in the duplicated cohort and tested for differences by including an interaction term between case-control status and the cohort indicator. Dependence between the cohorts was accommodated by using the sandwich variances estimate.
RESULTS
A total of 5,326 MGUS patients with 20,161 matched controls were included in the study. Demographic and clinical characteristics of the patients and controls are shown in Table 1 . The median age at diagnosis was 71 years, and 50% of patients were male.
MGUS isotype was available for 61% of patients, and was IgG, IgA, and IgM in 40%, 11%, and 10% respectively. Data on M-protein concentration at diagnosis was available for 53% of patients, of those 60% had above 10.0 g/L and 40% below ( Table 1 ).
Compared to controls MGUS patients had a significantly 1.7 (95% CI 1.6-1.9) and 1.6 (1.5-1.7) fold increased risk of any fracture, after 5 and 10 years of follow-up, respectively ( Table 2 ). There was no statistical difference in risk between males and females. When analysing specific anatomical sites of fractures, MGUS patients had a significantly increased 5-and 10-year risk of vertebral/pelvis (HR=2.7; 95 % CI 2.2-3.2 and HR=2.4; 95% CI 2.0-2.8), sternum/costae (HR=2.1; 95 % CI 1.5-2.9 and HR=1.9; 95% CI 1.5-2. Sensitivity analyses which excluded fractures occurring within 12 months before MM or WM diagnosis gave similar results (data not shown).
DISCUSSION
In this large study including more than 5,000 MGUS patients and their matched controls, we found that MGUS patients had an increased risk of fractures. Importantly, we did not find fractures to predict for MM or WM progression. Our findings provide further support for the development of osteoporosis prophylaxis strategies in MGUS patients and are of importance for the understanding of the underlying mechanisms for bone disease in MGUS and MM.
Available information on fracture risk in MGUS is restricted and typically based on small numbers. 2, 5, 8, 9 In one study including 488 MGUS patients, an increased risk was only observed for axial but not distal fractures. 2 In a screening study from the Mayo Clinic, based on 605 MGUS patients, a significantly increased risk was observed for vertebral, hip, and clavicle fractures, whereas there was no increase in the risk for fracture of long bones. 5 To our knowledge, these are the only two studies analysing risk of different types of fractures in MGUS patients. In contrast to these investigations, we observed an increased risk of many types of fractures after 5 and 10 years of follow-up, including fracture of the vertebra, pelvis, sternum, ribs, arms and legs. When we analysed axial and distal fractures separately, we found a higher risk for axial than distal fractures among IgG/IgA MGUS patients; however both were significantly higher compared to controls. Taken together, these data show that MGUS patients have an increased risk for fractures; however the higher risk in axial sites suggests that the underlying mechanism might be related to the production of hematopoietic marrow, primarily seen in axial bones. Interestingly, studies using more sensitive methods such as magnetic resonance imaging have detected more bone lesions than standard bone survey in multiple myeloma Our study has several strengths, including its large size as well as the application of high-quality data from Sweden, its population with access to standardised medical care during the entire study period. In our study, we used a register-based cohort design, which ensured a population-based setting and generalisation of our findings. As reported Registry. However, because we compared MGUS cases to matched controls, using data from the same registries, the ascertainment should be non-differential and any bias should be towards a null association.
In summary, compared to controls, we found patients with MGUS to have a significantly increased risk of several types of fractures. We did not find the occurrence of fracture to be a predictor of MM or WM progression among patients diagnosed with MGUS. Our findings are of relevance for the development of clinical studies designed to uncover pathogenesis and to prevent bone disease in early myelomagenesis.
Consequently, they may have implications for the development of future MM treatment strategies targeting the bone marrow microenvironment. Abbreviations: HR = hazard ratio, CI = confidence interval; ctrl = controls; * Adjusted for age, sex and calendar period; ** skull, vertebral/pelvis, sternum/costae; ***arm,
